News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca Canada Inc. (AZN) Expands Product Portfolio to Include Vaccines


8/18/2009 11:56:28 AM

MISSISSAUGA, ON, Aug. 18 /CNW/ - AstraZeneca Canada Inc. announced today that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada. Working in partnership with its biologics subsidiary MedImmune, AstraZeneca Canada intends to bring MedImmune's leading vaccine technology to Canadian patients through its FluMist product, which is administered intranasally. The proposed indication for FluMist is for the prevention of seasonal influenza.

Read at Canada NewsWire


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES